Dr. Jiayi Huang, M.D.
Claim this profileWashington University School of Medicine
Studies Glioblastoma
Studies Brain Tumor
19 reported clinical trials
35 drugs studied
About Jiayi Huang, M.D.
Education:
- Earned a B.A. in Biochemistry from Brandeis University, Waltham, MA (2001).
- Received an M.D. from the University of Massachusetts Medical School, Worcester, MA (2007).
Experience:
- Completed a Residency in Radiation Oncology at William Beaumont Hospital, Royal Oak, MI (2012).
- Holds the academic title of Associate Professor, Radiation Oncology; Chief, CNS/Gamma Knife Service.
- Specializes in Radiation Oncology with a clinical focus on brain tumors, skull base tumors, spinal tumors, and lymphoma.
- Affiliated with Barnes-Jewish Hospital and Christian Hospital, actively involved in research on molecular imaging and cancer stem cells.
Area of expertise
1Glioblastoma
IDH negative
Stage IV
MET positive
2Brain Tumor
IDH positive
IDH negative
MGMT negative
Affiliated Hospitals
Clinical Trials Jiayi Huang, M.D. is currently running
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
Personalized DNA Vaccine + PD-1 Blockade
for Glioblastoma
This is a single institution, open-label, multi-arm, phase I study assessing the safety and immunogenicity of a personalized neoantigen-based personalized DNA vaccine combined with PD-1 blockade therapy in subjects with newly diagnosed, MGMT promoter unmethylated glioblastoma (GBM). Immune checkpoint blockade, specifically those targeting the PD-1/PD-L1 pathways, has shown efficacy in multiple solid and hematologic malignancies. Furthermore, as has been demonstrated in metastatic melanoma, combining PD-1/PD-L1 blockade with other immune checkpoint inhibitors has shown improved objective response rates, though there is a significant increase in serious immune-related adverse events. As such, current trials are exploring different doses, administration schedules, and immune checkpoint agents. One alternative approach, however, is to introduce a tumor-directed therapy such as a personalized neoantigen vaccine combined with these immune modulating agents (i.e. immune checkpoint blocking antibodies) to maximize the tumor-specific response but minimize the toxicity associated with increasing non-specific systemic immune activation by generating a potent and focused neoantigen specific immune response. This study will test the hypothesis that a personalized neoantigen DNA vaccine in combination with concurrent administration of immune checkpoint blockade therapy will enhance the magnitude and breadth of neoantigen-specific T cell responses while maintaining an acceptable safety profile. The overall goal of this study is to identify the optimal vaccine plus adjuvant platform that can be tested in a subsequent phase II study to determine the efficacy of a personalized neoantigen vaccine approach in patients with GBM.
Recruiting1 award Phase 1
More about Jiayi Huang, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Jiayi Huang, M.D. has experience with
- Temozolomide
- Surgery
- Radiation Therapy
- Azeliragon
- Radiation Therapy
- Retifanlimab
Breakdown of trials Jiayi Huang, M.D. has run
Glioblastoma
Brain Tumor
Protoplasmic Astrocytoma
Meningioma
Oligodendroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jiayi Huang, M.D. specialize in?
Jiayi Huang, M.D. focuses on Glioblastoma and Brain Tumor. In particular, much of their work with Glioblastoma has involved IDH negative patients, or patients who are Stage IV.
Is Jiayi Huang, M.D. currently recruiting for clinical trials?
Yes, Jiayi Huang, M.D. is currently recruiting for 6 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Jiayi Huang, M.D. has studied deeply?
Yes, Jiayi Huang, M.D. has studied treatments such as Temozolomide, Surgery, Radiation Therapy.
What is the best way to schedule an appointment with Jiayi Huang, M.D.?
Apply for one of the trials that Jiayi Huang, M.D. is conducting.
What is the office address of Jiayi Huang, M.D.?
The office of Jiayi Huang, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.